Medigen Vaccine Biologics Corp. AI Stock Analysis
Medigen Vaccine Biologics Corp. (6547) AI Stock Analysis
Medigen Vaccine Biologics Corp.
(TPEx:6547)
Medigen Vaccine Biologics scores in the lower band, driven primarily by weak financial performance: revenue has stalled around NT$613 million post-COVID, the net loss widened materially in 2025, and both operating and free cash flow turned negative again. The main offset is a fortress-like balance sheet — minimal debt (D/E of 0.08) and equity funding nearly 90% of assets — which provides runway but is being steadily eroded by accumulated losses. Technicals add to the caution, with the price below all key moving averages and negative MACD momentum. Valuation provides no cushion given negative earnings and no dividend. With no earnings call or corporate event data available, the score rests on fundamentals, technicals and valuation alone.
Medigen Vaccine Biologics Corp. (6547) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 15.27B
- Dividend Yield
- ―
- Average Volume (3M)
- 4.15M
- Price to Earnings (P/E)
- -408.2
- Beta (1Y)
- 0.25
- Revenue Growth
- 44.37%
- EPS Growth
- 78.11%
- Country
- TW
- Employees
- 1,226
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Medigen Vaccine Biologics Corp. Business Overview & Revenue Model
Company Description
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III cli...
Medigen Vaccine Biologics Corp. Financial Statement Overview
Summary
A tale of two halves. The balance sheet is a genuine strength (score 68): equity of roughly NT$3.48 billion funds nearly 89% of assets, debt-to-equity is just 0.08, and leverage has been cut sharply since 2022 — giving the company real runway. However, earnings quality is poor (income statement 29): revenue has flatlined near NT$613 million (about 1% growth), gross margin slipped from roughly 65% to 59%, and the net loss widened to about NT$282 million from NT$80 million, leaving a net margin near -46%. Cash flow is also weak (35), with operating cash flow swinging back to roughly -NT$49 million and free cash flow at about -NT$100 million, though burn is a fraction of the 2022–2023 levels. Net result: a well-capitalized but structurally unprofitable developmental biotech that is still drawing down its equity cushion.
Income Statement
29NegativeBalance Sheet
68PositiveCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 573.85M | 613.17M | 605.64M | 389.62M | 365.04M | 3.28B |
| Gross Profit | 346.82M | 364.67M | 396.42M | 230.22M | -212.60M | 2.31B |
| EBITDA | -12.24M | -123.90M | 74.86M | -991.09M | -1.32B | 1.53B |
| Net Income | -166.77M | -281.71M | -80.47M | -1.16B | -1.50B | 1.41B |
Balance Sheet | ||||||
| Total Assets | 4.76B | 3.93B | 4.36B | 6.09B | 7.35B | 5.30B |
| Cash, Cash Equivalents and Short-Term Investments | 2.04B | 1.78B | 1.92B | 3.76B | 4.24B | 2.23B |
| Total Debt | 1.10B | 283.44M | 338.96M | 1.97B | 1.98B | 187.58M |
| Total Liabilities | 1.21B | 454.64M | 513.92M | 2.25B | 2.32B | 622.95M |
| Stockholders Equity | 3.56B | 3.48B | 3.85B | 3.85B | 5.03B | 4.68B |
Cash Flow | ||||||
| Free Cash Flow | -217.55M | -99.72M | 5.77M | -519.29M | -1.24B | 444.92M |
| Operating Cash Flow | -55.34M | -49.09M | 40.75M | -478.33M | -1.10B | 579.89M |
| Investing Cash Flow | -573.52M | -35.30M | 1.02B | 669.83M | -2.40B | -930.69M |
| Financing Cash Flow | 767.65M | -39.19M | -1.74B | 1.59M | 3.32B | 51.18M |
Medigen Vaccine Biologics Corp. Peers Comparison
Overall Rating
TW:411461Neutral
TW:178957Neutral
TW:414747Neutral- TW:654740Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4114 | 61Neutral | TWD 14.97B | 17.63 | ― | 3.05% | 11.40% | 9.36% |
| TW:1789 | 57Neutral | TWD 16.01B | 916.29 | ― | 1.43% | -4.75% | -90.91% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:4147 | 47Neutral | TWD 16.47B | -118.82 | ― | ― | 7.02% | 25.72% |
| TW:6547 | 40Underperform | TWD 16.94B | -408.17 | ― | ― | 44.37% | 78.11% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6547 | Medigen Vaccine Biologics Corp. | 51.50 | 14.00 | 37.33% | |
| TW:1789 | Scinopharm Taiwan, Ltd. | 20.25 | 2.75 | 15.70% | |
| TW:4114 | Synmosa Biopharma Corp | 27.85 | -1.93 | -6.48% | |
| TW:4147 | TaiMed Biologics Inc. | 60.30 | -6.90 | -10.27% | |
| TW:6586 | CHO Pharma, Inc. | 74.40 | 43.90 | 143.93% | |
| TW:6589 | EirGenix, Inc. | 51.40 | -16.40 | -24.19% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026